000			01924 a2200565 4500
005			20250517042435.0
264		0	_c20161213
008			201612s 0 0 eng d
022			_a1468-1293
024	7		_a10.1111/hiv.12281 _2doi
040			_aNLM _beng _cNLM
100	1		_aWohl, D A
245	0	0	_aThe ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. _h[electronic resource]
260			_bHIV medicine _cFeb 2016
300			_a106-17 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAnti-HIV Agents _xtherapeutic use
650	0	4	_aAntiretroviral Therapy, Highly Active
650	0	4	_aAtazanavir Sulfate _xtherapeutic use
650	0	4	_aBiomarkers _xblood
650	0	4	_aBone Density _xdrug effects
650	0	4	_aCD4 Lymphocyte Count
650	0	4	_aDideoxynucleosides _xtherapeutic use
650	0	4	_aDrug Combinations
650	0	4	_aDrug Substitution _xmethods
650	0	4	_aFemale
650	0	4	_aHIV Infections _xblood
650	0	4	_aHumans
650	0	4	_aKidney _xdrug effects
650	0	4	_aLamivudine _xtherapeutic use
650	0	4	_aLipids _xblood
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aRNA, Viral _xblood
650	0	4	_aRitonavir _xadverse effects
650	0	4	_aTreatment Outcome
650	0	4	_aViral Load
700	1		_aBhatti, L
700	1		_aSmall, C B
700	1		_aEdelstein, H
700	1		_aZhao, H H
700	1		_aMargolis, D A
700	1		_aDeJesus, E
700	1		_aWeinberg, W G
700	1		_aRoss, L L
700	1		_aShaefer, M S
773	0		_tHIV medicine _gvol. 17 _gno. 2 _gp. 106-17
856	4	0	_uhttps://doi.org/10.1111/hiv.12281 _zAvailable from publisher's website
999			_c25075871 _d25075871